CLINICAL TRIALS PROFILE FOR MAVORIXAFOR
✉ Email this page to a colleague
All Clinical Trials for MAVORIXAFOR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03005327 ↗ | A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | Active, not recruiting | X4 Pharmaceuticals | Phase 2 | 2016-12-01 | This is a Phase 2 study with an initial 24-week Treatment Period and an Extension Phase. The primary objectives of this Phase 2 study are to determine the safety, tolerability, and dose selection of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in an Extension Phase, if regionally applicable, until it becomes commercially available or until the study is terminated by the Sponsor. |
| NCT03995108 ↗ | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | Active, not recruiting | X4 Pharmaceuticals | Phase 3 | 2019-10-17 | This study has a double-blind, placebo-controlled Randomized Period and an Open-Label extension Period. The primary objective of the Randomized Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils compared with placebo, and relative to a clinically meaningful threshold. The primary objective of the Open-Label Period is to evaluate the safety and tolerability of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in the Open-Label extension Period, if regionally applicable, until mavorixafor becomes commercially available, or until the study is terminated by the Sponsor. |
| NCT04154488 ↗ | A Study of Mavorixafor in Participants With Severe Congenital Neutropenia and Chronic Neutropenia Disorders | Recruiting | X4 Pharmaceuticals | Phase 1 | 2020-10-16 | This Phase 1b study will determine the safety and tolerability of mavorixafor in participants with severe chronic idiopathic neutropenia (CIN) and selected congenital neutropenia disorders. The anticipated enrollment is up to 25 participants. |
| NCT04274738 ↗ | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | Recruiting | X4 Pharmaceuticals | Phase 1 | 2020-04-30 | The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK) and pharmacodynamic (PD) data to select the recommended dose for a randomized registrations trial. |
| NCT06056297 ↗ | A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Not yet recruiting | X4 Pharmaceuticals | Phase 3 | 2024-03-01 | The purpose of this study is to demonstrate the efficacy and evaluate the safety, and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MAVORIXAFOR
Condition Name
Clinical Trial Locations for MAVORIXAFOR
Trials by Country
Clinical Trial Progress for MAVORIXAFOR
Clinical Trial Phase
Clinical Trial Sponsors for MAVORIXAFOR
Sponsor Name
